Welcome to our dedicated page for ALNYLAM PHARMACEUTICALS SEC filings (Ticker: ALNY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alnylam Pharmaceuticals filings document the regulatory record for a Nasdaq-listed biopharmaceutical company built around RNA interference therapeutics. Recent Form 8-K reports furnish operating results and financial condition updates tied to product revenues from AMVUTTRA, ONPATTRO, GIVLAARI and OXLUMO, while other current reports disclose strategy updates, pipeline goals and clinical-program context.
The filing record also covers governance and capital structure matters, including the definitive proxy statement, executive compensation and equity-award disclosures, common stock registered on Nasdaq, a revolving credit facility and convertible senior note offering materials. These disclosures describe board oversight, compensation plans, financing arrangements, material corporate events and the formal exhibits supporting Alnylam's public-company reporting.
ALNYLAM PHARMACEUTICALS, INC. executive Bryan Supran, EVP, CLO and Secretary, reported equity awards consisting of stock options and restricted stock units. He received stock options for 3,381 shares at an exercise price of $0.00 per share, and a grant of 1,539 shares of common stock represented by restricted stock units.
The RSUs vest over three years, with one third vesting on each of the first, second and third anniversaries of the grant date, conditioned on continued service. The stock options vest 25% on the first anniversary of the grant date, with the remainder vesting in equal quarterly installments until the fourth anniversary, also subject to continuous service.
ALNYLAM PHARMACEUTICALS, INC. reported multiple equity transactions for Chief Executive Officer Yvonne Greenstreet. She received a grant of 30,425 stock options and 110,746 stock price performance stock units, both at a price of $0.00 per share. She also acquired 13,844 shares of common stock, including restricted stock units under the 2018 Stock Incentive Plan that vest over three years and shares acquired through the company’s 401(k) matching program. On the same date, a total of 6,799 shares of common stock were sold in a series of market transactions at weighted average prices around $323–$333 per share, which the company indicates were automatically sold to cover minimum statutory tax withholding obligations on the awards. Following these transactions, she directly held 98,628 shares of common stock and maintained additional indirect ownership through a managed account, and the performance units may vest on December 31, 2029 depending on future stock price performance.
Alnylam Pharmaceuticals reported that its board granted a special, fully performance-based equity award to CEO Yvonne Greenstreet under the 2018 Stock Incentive Plan. The award targets 55,373 performance share units, with a face value of $18.0 million based on the $325.07 share price on the grant date.
The units can vest only if the company’s stock achieves demanding average price hurdles between $500 and $800 over a 30‑day period before December 31, 2029, allowing 50% to 200% of target shares to vest. If the stock does not reach $500, the award is forfeited. Continued service is generally required, with modified treatment for certain terminations and change in control events.
ALNY affiliate submitted a Form 144 notice of proposed sales of company common stock derived from restricted stock units. The filing lists proposed RSU sales of 847 shares on 02/27/2026 and 805 shares on 03/02/2026. The filing also reports prior dispositions by Kevin Fitzgerald of 2,290 shares on 01/13/2026 for $848,062.57 and 2,041 shares on 02/17/2026 for $677,531.58.
ALNY insider sale: Pushkal Garg reported the sale of 4,627 Common shares on 02/27/2026, with the filing showing an associated dollar figure of $1,533,106.94.
The filing also lists issuer-designated RSU entries of 970 shares on 02/27/2026 and 805 shares on 03/01/2026.
ALNYLAM PHARMACEUTICALS, INC. Chief Executive Officer Yvonne Greenstreet reported the vesting and conversion of 5,921 restricted stock units into an equal number of common shares on February 27, 2026. These RSUs were part of a 17,763-unit grant from February 27, 2023 that vests in three equal annual installments.
Following this derivative exercise, her directly held common stock increased to 91,583 shares. She also has 407 common shares held indirectly in a managed account. The transaction reflects equity compensation vesting, not an open-market purchase or sale.
ALNYLAM PHARMACEUTICALS, INC. executive vice president and chief financial officer Jeffrey V. Poulton reported the vesting of restricted stock units that converted into common shares. On February 27, 2026, 1,908 restricted stock units were exercised at $0.00 and settled into 1,908 shares of common stock.
These RSUs were part of a 5,724‑unit grant awarded on February 27, 2023, which vested in three equal annual installments. The filing notes that this transaction represents the third and final tranche from that grant. Following the conversion, Poulton directly owned 61,710 shares of common stock, and an additional 57 shares were held indirectly through a managed account.
Alnylam Pharmaceuticals executive Tolga Tanguler acquired shares through equity compensation. On February 27, 2026, 1,666 restricted stock units were exercised at $0.00 per share and converted into 1,666 shares of common stock, increasing his directly held stake to 33,435 shares.
These RSUs were part of a 5,000-unit grant awarded on February 27, 2023 under the company’s Amended and Restated 2018 Stock Incentive Plan. The award vested in three equal annual installments, and this filing reflects the third and final tranche becoming fully vested and released.
ALNYLAM PHARMACEUTICALS, INC. executive vice president and Chief R&D officer Pushkal Garg reported both an equity award vesting and share sales. On February 27, 2026, 1,908 restricted stock units were converted into common shares at no cost as the final tranche of a February 27, 2023 grant vested. That same day, he sold a total of 4,627 shares of common stock in multiple open-market transactions at prices ranging from about $328.92 to $334.39 per share under a pre-established Rule 10b5-1 trading plan adopted on November 20, 2025. After these transactions, he directly held 22,129 common shares, with additional shares held indirectly in a managed account and in a trust where his spouse is co-trustee, and he disclaims beneficial ownership of the trust shares.